Information Library

Results for: Emerging Biopharma

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Quintiles Addresses Key Considerations for Successful Biosimilar Development

    Press Release — September 29, 2011 – Regulatory and commercial considerations are the primary drivers for successful biosimilar development, according to a new report from Quintiles.

  • Partnering is Key to Maximizing Rewards in Emerging Markets

    Press Release — September 27, 2011 – While biopharmaceutical spending in emerging markets is growing at double-digit rates – much faster than in developed nations – opportunities in “pharmerging” countries must be balanced with accompanying costs and risks of entering new markets.

  • Patty James, B.S., MT (ASCP)

    Bio — August 11, 2010
    Patty James is an experienced relationship manager responsible for coordinating clinical trial logistics and operations for biomarker projects in oncology.

  • Emerging Biopharma Service Fact Sheet

    Brochure — May 4, 2010
    Recognizing that the needs of emerging companies are unique, Quintiles has created a specialized team dedicated exclusively to small and mid-sized biopharma companies.

  • PharmAsia News Article Reprint

    Media Coverage — March 1, 2010
    Quintiles Asia Executives Say CROs Must Evaluate, Adjust To New Health Landscape: An Interview With PharmAsia News.

  • BIOS Standardize Data with SPARC

    Brochure — February 2, 2010
    There is an increasing global requirement for Clinical Data Interchange Standards Consortium (CDISC) -based standardized data for regulatory submissions. At Quintiles, we have proactively addressed this need by training our staff, gaining experience, and developing and implementing innovative solutions for creating data that adhere to current CDISC Study Data Tabulation Model (SDTM) specifications.

  • Enabling Transformation

    Case Study — September 30, 2009
    Biovitrum found an ideal opportunity to transform itself into a fully integrated specialty pharmaceutical company from a biotech discovery and early clinical development company.

  • Should Venture Firms Bundle Their Biotech Portfolios?

    Media Coverage — June 29, 2009
    Ron Wooten, president of the investment and business-development unit of Quintiles, a contract-research organization, thinks so.

Page 1 of 1 (8 results)

Subscribe to Email Based on Your Interests

Set preferences